The latest price target for Vincerx Pharma (NASDAQ:VINC) was reported by Cantor Fitzgerald on April 9, 2024. The analyst firm set a price target for $0.00 expecting VINC to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ:VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.

There is no last upgrade for Vincerx Pharma

There is no last downgrade for Vincerx Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $0.00. The current price Vincerx Pharma (VINC) is trading at is $0.71, which is out of the analyst’s predicted range.